Sotera Health Co. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Sotera Health Company for the fiscal year ended December 31, 2025. Sotera is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services for the healthcare industry. The company operates through three reportable segments: Sterigenics (terminal sterilization services), Nordion (Cobalt-60 supply and gamma irradiation systems), and Nelson Labs (microbiological and analytical lab testing). As of December 31, 2025, the company operated 62 facilities worldwide with over 3,000 employees.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Net Revenues | $1,163.6 million | $1,100.4 million | +5.7% |
| Net Income (GAAP) | $77.9 million | $44.4 million | +75.6% |
| Adjusted Net Income | $245.4 million | $198.5 million | +23.6% |
| Adjusted EBITDA | $593.8 million | $548.6 million | +8.2% |
| Operating Cash Flow | $287.2 million | $224.2 million | +28.1% |
| Total Debt | $2,169.5 million | $2,255.6 million | -3.8% |
| Cash and Equivalents | $346.5 million | $278.9 million | +24.2% |
| Capital Expenditures | $138.0 million | $179.1 million | -22.9% |
Segment Performance: All three segments reported income growth. Sterigenics revenue grew 8.3% to $755.8 million; Nordion revenue grew 8.2% to $187.6 million; Nelson Labs revenue declined 3.9% to $220.2 million due to a decrease in expert advisory services, though segment income increased 6.0%.
Material Changes vs. Prior Period
- Revenue Growth: Driven by favorable pricing and volume/mix across Sterigenics and Nordion. Service revenues increased 5.7% and product revenues increased 5.8%.
- Profitability: Net income increased significantly (75.6%) primarily due to a reduction in amortization of intangible assets ($31.3 million decrease) and lower interest expense (weighted average rate dropped to 7.29% from 8.16%).
- Debt Restructuring: In September 2025, the company entered into Amendment No. 6 to its Credit Agreement, repricing term loans to reduce the interest rate spread to Adjusted Term SOFR + 2.50% and extending the maturity to May 2031. In April 2025, the Revolving Credit Facility was increased and extended to 2030.
- Amortization: A significant decline in amortization expense occurred as certain intangible assets were fully amortized by May 2025.
Guidance, Outlook, Risks, and Contingencies
Outlook and Capital Allocation: The company expects to continue investing in facility expansions, Co-60 supply development, and environmental enhancements. For 2026, approximately $51 million of capital expenditures are estimated for environmental facility enhancements. The company maintains a disciplined acquisition strategy.
Key Risks and Contingencies:
- Ethylene Oxide (EO) Litigation: The company faces ongoing tort litigation in California, Georgia, Illinois, and New Mexico alleging health impacts from EO emissions. In 2025, the company settled 226 claims in Illinois for a total of $64.9 million. While the company denies the allegations, future settlements are considered reasonably possible. Insurance coverage for these claims is limited or exhausted.
- Regulatory Compliance: The company is subject to evolving regulations regarding EO emissions (e.g., EPA NESHAP rules) and Co-60 supply. A White House proclamation in July 2025 granted a two-year exemption for certain sterilization facilities to install new control technology, though this is subject to legal challenge.
- Supply Chain: Approximately 20% of long-term Co-60 supply is generated by Russian nuclear reactors, with potential exposure increasing to 50% in certain years due to outages elsewhere. Geopolitical sanctions and logistics challenges pose a risk to supply continuity.
- Debt Covenants: The company carries significant leverage ($2.17 billion). An event of default could occur if enforceable judgments exceed the greater of $162.6 million or 30% of consolidated EBITDA and remain undischarged for 60 days.
Investor Verification Checklist
- EO Litigation Exposure: Verify the status of pending cases in Georgia and California and the potential for future settlements beyond the $64.9 million paid in 2025.
- Co-60 Supply Security: Assess the impact of geopolitical sanctions on Russian reactor operators and the timeline for new U.S. production capabilities (e.g., PSEG, Darlington).
- Regulatory Capital Expenditures: Confirm the sufficiency of the projected $51 million in 2026 environmental capex to meet EPA NESHAP and FIFRA requirements.
- Debt Service Capacity: Monitor Adjusted EBITDA trends to ensure compliance with debt covenants, particularly given the risk of large litigation judgments triggering default.
- Nelson Labs Revenue Mix: Evaluate the sustainability of the decline in expert advisory services revenue and the growth trajectory of core lab testing.